|
Market Closed -
Nasdaq
00:00:01 31/10/2026 +04
|
5-day change | 1st Jan Change | ||
| 3.090 USD | -7.49% |
|
-2.22% | +6.19% |
| 10-16 | Indaptus Therapeutics, Inc. announced that it has received $23.999989 million in funding | CI |
| 09-10 | Indaptus Therapeutics Shares Rise After Entering $24 Million Private Placement | MT |
Company Valuation: Indaptus Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Market Cap 1 | 46.7 | 12.18 | 14.79 | 10.12 | 5.096 |
| Change | - | -73.92% | 21.38% | -31.58% | -49.63% |
| Enterprise Value (EV) 1 | 7.74 | -14.17 | 1.599 | 4.414 | -3.412 |
| Change | - | -283.08% | 111.28% | 176.1% | -177.29% |
| P/E | -3.02x | -0.84x | -0.96x | -0.52x | -0.13x |
| PBR | 1.31x | 0.49x | 1.22x | 2.56x | 2.01x |
| PEG | 0x | 0.1x | -0.16x | 0x | 0x |
| Capitalization / Revenue | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - |
| EV / EBITDA | -1x | 0.95x | -0.1x | -0.29x | 0.17x |
| EV / EBIT | -1x | 0.95x | -0.1x | -0.29x | 0.17x |
| EV / FCF | -3.89x | 2x | -0.21x | -0.64x | 0.42x |
| FCF Yield | -25.7% | 49.9% | -486% | -155% | 239% |
| Dividend per Share 2 | - | - | - | - | - |
| Rate of return | - | - | - | - | - |
| EPS 2 | -52.78 | -48.54 | -51.41 | -44.96 | -21.58 |
| Distribution rate | - | - | - | - | - |
| Net sales | - | - | - | - | - |
| EBITDA 1 | -7.728 | -14.91 | -16.38 | -15.37 | -19.83 |
| EBIT 1 | -7.729 | -14.91 | -16.38 | -15.37 | -19.83 |
| Net income 1 | -7.711 | -14.32 | -15.42 | -15.02 | -20.85 |
| Net Debt 1 | -38.96 | -26.35 | -13.19 | -5.703 | -8.508 |
| Reference price 2 | 159.600 | 40.600 | 49.280 | 23.579 | 2.910 |
| Nbr of stocks (in thousands) | 293 | 300 | 300 | 429 | 1,751 |
| Announcement Date | 21/03/22 | 17/03/23 | 13/03/24 | 13/03/25 | 17/03/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 475M | |
| 16.87x | 6.34x | 12.15x | 1.77% | 63.77B | |
| 30.14x | 8.25x | 27.02x | 0.04% | 56.37B | |
| 37.48x | 6.65x | 19.86x | 0.86% | 54.62B | |
| 34.85x | 3.31x | 14.29x | -.--% | 44.06B | |
| 48.85x | 5.63x | 30.81x | -.--% | 42.11B | |
| -19.86x | 192.36x | -21.16x | -.--% | 41B | |
| 47.33x | 8.41x | 28.18x | -.--% | 34.92B | |
| 32x | 8.13x | 21.15x | 0.41% | 32.82B | |
| -71.62x | 13.03x | -68.47x | -.--% | 24.7B | |
| Average | 17.34x | 28.01x | 7.09x | 0.34% | 39.48B | |
| Weighted average by Cap. | 21.64x | 26.34x | 11.23x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- INDP Stock
- Valuation Indaptus Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
